{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
AtriCure, Inc. Stock Plummets to New 52-Week Low of $27.09
AtriCure, Inc. has reached a new 52-week low, reflecting its current market challenges. With a market capitalization of USD 1,516 million, the company has underperformed compared to the S&P 500 over the past year. AtriCure is currently loss-making and does not offer a dividend yield.
AtriCure, Inc. Hits New 52-Week Low at $27.31
AtriCure, Inc. has reached a new 52-week low of USD 27.31, down from a high of USD 43.18, highlighting its stock volatility. Despite this, the company has achieved a 1-year performance of 28.38%, surpassing the S&P 500. AtriCure's market cap is USD 1,516 million, but it remains loss-making.
AtriCure, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
AtriCure, Inc., a small-cap company in the Pharmaceuticals and Biotechnology sector, has experienced a decline in stock price and performance compared to the S&P 500. Technical indicators suggest a bearish sentiment, with mixed signals on various time frames, reflecting ongoing challenges in the current market environment.
AtriCure, Inc. Experiences Revision in Stock Evaluation Amidst Market Challenges
AtriCure, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has seen its stock price decline recently. Over the past year, it has faced significant challenges, with a notable negative return compared to the S&P 500. Technical indicators suggest a bearish sentiment in the market.
AtriCure Stock Forms Death Cross, Signaling Bearish Trend Ahead
AtriCure, Inc. has recently encountered a technical event known as a Death Cross, indicating a bearish trend. Current indicators, including moving averages and MACD, support this outlook. The company has faced a 12.43% decline over the past year, significantly underperforming the S&P 500. Year-to-date, the stock is down 25.23%.
AtriCure, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
AtriCure, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a decline in stock price and significant challenges over the past year, with a return of -19.92%. The company's performance indicators show mixed signals, reflecting ongoing difficulties in a competitive market.
Is AtriCure, Inc. technically bullish or bearish?
As of October 31, 2025, AtriCure, Inc. shows a mildly bullish technical trend, with mixed signals from MACD and moving averages, but has underperformed the S&P 500 with a year-to-date return of 7.17% compared to 16.30%.
Is AtriCure, Inc. technically bullish or bearish?
As of October 31, 2025, AtriCure, Inc. shows a mildly bullish trend supported by daily moving averages and monthly KST signals, but mixed indicators from weekly MACD and Bollinger Bands suggest caution, especially given its underperformance compared to the S&P 500.
Is AtriCure, Inc. technically bullish or bearish?
As of October 31, 2025, AtriCure, Inc. shows a mildly bullish technical trend with positive momentum indicators, but mixed signals from the OBV and underperformance compared to the S&P 500 suggest caution.
Is AtriCure, Inc. technically bullish or bearish?
As of October 31, 2025, AtriCure, Inc. shows a mildly bullish technical trend with positive momentum from MACD and moving averages, but mixed signals from OBV and performance lagging behind the S&P 500 suggest caution.
Is AtriCure, Inc. technically bullish or bearish?
As of September 12, 2025, AtriCure, Inc. has a neutral technical trend with mixed indicators, outperforming the S&P 500 year-to-date and over the past year, but showing significantly negative long-term returns compared to the index.
Is AtriCure, Inc. overvalued or undervalued?
As of November 1, 2022, AtriCure, Inc. has shifted to a risky valuation grade, appearing overvalued with concerning metrics such as a Price to Book Value of 3.80, a negative ROCE of -5.50%, and a P/E ratio of -92.43, despite a strong year-to-date return of 19.96%, which still lags behind the S&P 500 over the long term.
AtriCure, Inc. Experiences Evaluation Revision Amidst Mixed Market Signals and Performance Trends
AtriCure, Inc. has recently revised its evaluation amid changing market conditions. The stock is priced at $34.63, with a notable annual return of 22.76%, surpassing the S&P 500. Technical indicators show mixed signals, suggesting a need for close monitoring of the company's performance in the current market landscape.
Is AtriCure, Inc. overvalued or undervalued?
As of November 1, 2022, AtriCure, Inc. is considered overvalued with significant operational challenges reflected in negative earnings and poor return metrics, despite a 39.06% return over the past year, indicating a shift from fair to risky valuation.
Is AtriCure, Inc. technically bullish or bearish?
As of June 5, 2025, the market trend is mildly bearish, indicated by bearish signals from the weekly MACD, KST, and daily moving averages, despite some bullish signs in monthly indicators.
Who are in the management team of AtriCure, Inc.?
As of March 2022, the management team of AtriCure, Inc. includes Scott Drake (Independent Chairman), Michael Carrel (CEO), and several independent directors: Mark Collar, Daniel Florin, Regina Groves, B. Kristine Johnson, and Mark Lanning. They oversee the company's strategic direction and operations.
What does AtriCure, Inc. do?
AtriCure, Inc. develops and sells devices for surgical ablation of cardiac tissue and left atrial appendage exclusion, focusing on atrial fibrillation solutions. As of March 2025, it reported net sales of $124 million and a net loss of $7 million, with a market cap of approximately $1.61 billion.
How big is AtriCure, Inc.?
As of Jun 18, AtriCure, Inc. has a market capitalization of $1.61 billion, with net sales of $480.08 million and a net profit of -$38.18 million over the latest four quarters. Shareholder's funds are $460.97 million, and total assets amount to $609.33 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
